Filtros de búsqueda

Lista de obras de

A comparison of the efficacy of immunomodulatory-free regimens in relapsed or refractory multiple myeloma: a network meta-analysis

scientific article published on 08 November 2018

A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and "pan-leukemia" antigens

artículo científico publicado en 2017

A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas

artículo científico publicado en 2010

A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation

artículo científico publicado en 2016

Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial

artículo científico publicado en 2019

Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p

scientific article published on 08 December 2011

Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis.

artículo científico publicado en 2017

Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma

artículo científico publicado en 2016

Autologous stem cell transplantation in multiple myeloma patients: utilization patterns and hospital effects

artículo científico publicado en 2020

Automated "Bone Subtraction" Image Analysis Software Package for Improved and Faster CT Monitoring of Longitudinal Spine Involvement in Patients with Multiple Myeloma

artículo científico publicado en 2017

BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee

artículo científico publicado en 2017

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

scientific article published on 16 December 2019

Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial

artículo científico publicado en 2013

Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma

artículo científico publicado en 2018

Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age

artículo científico publicado en 2020

Can whole-body low-dose multidetector CT exclude the presence of myeloma bone disease in patients with monoclonal gammopathy of undetermined significance (MGUS)?

artículo científico publicado en 2012

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

artículo científico publicado en 2015

Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials

artículo científico publicado en 2019

Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup.

artículo científico publicado en 2017

Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial

artículo científico publicado en 2017

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study

artículo científico publicado en 2020

Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study

artículo científico publicado en 2017

Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients

scholarly article by Katharina Kriegsmann et al published 29 January 2019 in Blood Cancer Journal

Classical hodgkin lymphoma as de novo B-cell malignancy after treatment of multiple myeloma in the pre-lenalidomide era.

artículo científico publicado en 2013

Comparison of three different serum-free light-chain assays-implications on diagnostic and therapeutic monitoring of multiple myeloma

artículo científico publicado en 2020

Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma

artículo científico publicado en 2015

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma

article

Corrigendum to "Simplified response monitoring criteria for multiple myeloma in patients undergoing therapy with novel agents using computed tomography" [Eur. J. Radiol. 85 (December (12)), 2016, 2195-2199]

scientific article published on 03 May 2018

Critical Appraisal of Published Indirect Comparisons and Network Meta-Analyses of Competing Interventions for Multiple Myeloma

scientific article published on 06 April 2020

Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE.

artículo científico publicado en 2017

Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myeloma

scientific article published on 27 August 2019

Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone.

artículo científico publicado en 2015

DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma

artículo científico publicado en 2009

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

artículo científico publicado en 2019

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR

scholarly article by Andrew Spencer et al published 20 September 2018 in Haematologica

Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR

scientific article published on 09 October 2019

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

artículo científico publicado en 2016

Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk

artículo científico publicado en 2020

Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies

scientific article published on 31 January 2020

Development of an Initial Conceptual Model of Multiple Myeloma to Support Clinical and Health Economics Decision Making

Differential effects of G protein coupled receptors on hematopoietic progenitor cell growth depend on their signaling capacities

artículo científico publicado en 2007

Dual-energy CT: virtual calcium subtraction for assessment of bone marrow involvement of the spine in multiple myeloma.

artículo científico publicado en 2015

Early response assessment in patients with multiple myeloma during anti-angiogenic therapy using arterial spin labelling: first clinical results

artículo científico publicado en 2010

Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma

artículo científico publicado en 2020

Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR

artículo científico publicado en 2020

Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial

artículo científico publicado en 2018

Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study

artículo científico publicado en 2020

Epstein-Barr virus-associated B-cell lymphoma secondary to FCD-C therapy in patients with peripheral T-cell lymphoma

artículo científico publicado en 2008

European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): a randomised control trial.

artículo científico publicado en 2008

Extended in vitro expansion of adult, mobilized CD34+ cells without significant cell senescence using a stromal cell coculture system with single cytokine support

artículo científico publicado en 2009

Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma

artículo científico publicado en 2017

First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma

scientific article published on 22 January 2020

Follow-up of patients with refractory or relapsed multiple myeloma after allogeneic hematopoietic cell transplantation.

artículo científico publicado en 2017

Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trial.

artículo científico publicado en 2016

Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison

artículo científico publicado en 2020

Genetic and functional characterization of isolated stromal cell lines from the aorta-gonado-mesonephros region

artículo científico publicado en 2005

Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial

artículo científico publicado en 2020

Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma

artículo científico publicado en 2014

Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma

article

Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma, based on German benefit assessment data

artículo científico publicado en 2019

Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma

scientific article published on 09 April 2020

High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial

artículo científico publicado en 2019

INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma

scientific article published on 28 February 2019

Imaging findings in relapsing multiple myeloma

artículo científico publicado en 2009

Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma.

artículo científico publicado en 2015

Improved Follow-Up and Response Monitoring of Thoracic Cage Involvement in Multiple Myeloma Using a Novel CT Postprocessing Software: The Lessons We Learned

artículo científico publicado en 2016

Improved MDCT monitoring of pelvic myeloma bone disease through the use of a novel longitudinal bone subtraction post-processing algorithm

artículo científico publicado en 2016

Improvement of diagnostic confidence for detection of multiple myeloma involvement of the ribs by a new CT software generating rib unfolded images: Comparison with 5- and 1-mm axial images

artículo científico publicado en 2015

Increasing bone sclerosis during bortezomib therapy in multiple myeloma patients: results of a reduced-dose whole-body MDCT study.

artículo científico publicado en 2014

Intensive Care Outcomes of Patients after High Dose Chemotherapy and Subsequent Autologous Stem Cell Transplantation: A Retrospective, Single Centre Analysis

artículo científico publicado en 2020

Intravascular lymphoma - a rare cause of hemolytic anemia and neurologic disorders

artículo científico publicado en 2004

Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma

scientific article published on 27 September 2019

Lenalidomide

artículo científico

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma

artículo científico publicado en 2014

Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatment

artículo científico publicado en 2014

Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma

artículo científico publicado en 2021

Longitudinal fluorescence in situ hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation.

artículo científico publicado en 2017

MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial

scientific article published on 11 March 2020

Maintenance and continuous therapy for multiple myeloma

artículo científico publicado en 2018

Mass spectrometry-based identification of a B-cell maturation antigen-derived T-cell epitope for antigen-specific immunotherapy of multiple myeloma ⬇️

scientific article published on 28 February 2020

Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone

artículo científico publicado en 2022

Modulation of CXC chemokine receptor expression and function in human neutrophils during aging in vitro suggests a role in their clearance from circulation

artículo científico publicado en 2009

OP9 stroma augments survival of hematopoietic precursors and progenitors during hematopoietic differentiation from human embryonic stem cells

artículo científico publicado en 2008

Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study

artículo científico publicado en 2018

Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis

artículo científico publicado en 2020

Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma

artículo científico publicado en 2019

Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone

Paraneoplastic granulocyte colony-stimulating factor secretion in soft tissue sarcoma mimicking myeloproliferative neoplasia: a case report

artículo científico publicado en 2014

Pathologic fractures in patients with multiple myeloma undergoing bisphosphonate therapy: incidence and correlation with course of disease

artículo científico publicado en 2009

Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial.

artículo científico publicado en 2016

Perspectives on the Risk-Stratified Treatment of Multiple Myeloma

Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial

artículo científico publicado en 2018

Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial

artículo científico publicado en 2015

Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials

artículo científico publicado en 2016

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

artículo científico publicado en 2013

Pomalidomide – An Appraisal of Its Clinical Development and Role in the Treatment of Relapsed/Refractory Multiple Myeloma

Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse

artículo científico publicado en 2020

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

scientific article published on 13 May 2019

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network.

artículo científico publicado en 2018

Progressive bicytopenia due to persistent parvovirus B19 infection after immunochemotherapy with fludarabine/cyclophosphamide and rituximab for relapsed B cell lymphoma.

artículo científico publicado en 2006

Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial

scientific article published on 26 June 2019

Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population

artículo científico publicado en 2019

Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transpla

artículo científico publicado en 2016

Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma

article

Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network

artículo científico publicado en 2020

Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS).

artículo científico publicado en 2016

Relative efficacy of treatment options in transplant-ineligible newly diagnosed multiple myeloma: results from a systematic literature review and network meta-analysis

scientific article published on 11 November 2019

Response Assessment in Patients with Multiple Myeloma during Antiangiogenic Therapy using Arterial Spin Labeling and Diffusion-Weighted Imaging ⬇️

artículo científico publicado el 1 de noviembre de 2010

Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial

artículo científico publicado en 2020

Role of dynamic contrast-enhanced sonography for characterization and monitoring of extramedullary myeloma: comparison with serologic data

artículo científico publicado en 2013

Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma

artículo científico publicado en 2016

Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE

artículo científico publicado en 2020

Selective elimination of immunosuppressive T cells in patients with multiple myeloma

artículo científico publicado en 2021

Simplified response monitoring criteria for multiple myeloma in patients undergoing therapy with novel agents using computed tomography

artículo científico publicado en 2016

Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date

artículo científico publicado en 2016

Stromal cell lines from the aorta-gonado-mesonephros region are potent supporters of murine and human hematopoiesis

artículo científico publicado en 2006

Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial.

artículo científico publicado en 2015

Successful use of eculizumab for treatment of an acute hemolytic reaction after ABO-incompatible red blood cell transfusion

artículo científico publicado en 2014

Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling

artículo científico publicado en 2018

Survival of elderly patients with multiple myeloma-Effect of upfront autologous stem cell transplantation

artículo científico publicado en 2016

The BCL2 E17 and SP66 antibodies discriminate 2 immunophenotypically and genetically distinct subgroups of conventionally BCL2-"negative" grade 1/2 follicular lymphomas

artículo científico publicado en 2013

The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy

artículo científico publicado en 2015

The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myeloma

scholarly article by Mohamed H S Awwad et al published 2018 in OncoImmunology

Treatment with Thalidomide and Cyclophosphamide (TCID) is Superior to Vincristine (VID) and to Vinorelbine (VRID) Regimens in Patients with Refractory or Recurrent Multiple Myeloma

artículo científico publicado en 2011

Whole-body diffusion-weighted MRI with apparent diffusion coefficient mapping for early response monitoring in multiple myeloma: preliminary results

artículo científico publicado en 2011

Wnt1 overexpression leads to enforced cardiomyogenesis and inhibition of hematopoiesis in murine embryonic stem cells

artículo científico publicado en 2010

[Monoclonal Gammopathy Of Unknown Significance - A Common Incidental Finding - What is to be thought of? What has to be done?]

artículo científico publicado en 2019

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda